Tag archive for ‘Palforzia’
By pharmanewsdaily On Tuesday, September 1st, 2020

Nestlé to fully own Aimmune Therapeutics through $2bn deal

Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in the latter for about $2 billion. The deal is expected More...

By pharmanewsdaily On Tuesday, March 17th, 2020

First patients being treated with Aimmune’s PALFORZIA peanut allergy drug

Aimmune Therapeutics said that the first patients in the US are being treated with the recently FDA approved peanut allergy drug PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. The California-based biopharma More...

By pharmanewsdaily On Sunday, February 9th, 2020

Nestlé increases stake in Aimmune Therapeutics after Palforzia FDA approval

Aimmune Therapeutics, which has recently bagged approval from the US Food and Drug Administration (FDA) for its peanut allergy drug PALFORZIA (formerly AR101), has secured an additional equity investment of $200 More...

By pharmanewsdaily On Monday, February 3rd, 2020

Aimmune Therapeutics bags Palforzia FDA approval for peanut allergy

Palforzia FDA approval : Aimmune Therapeutics has been granted approval from the US Food and Drug Administration (FDA) for Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] for the treatment of peanut allergy More...